Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos

Myriam Vanessa Rueda-Galvis; Isabel Cristina Ramírez-Sánchez; Carlos E. Builes-Montaño; Alejandro Vélez-Hoyos

doi:10.36384/01232576.609

Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos

Myriam Vanessa Rueda-Galvis, Isabel Cristina Ramírez-Sánchez, Carlos E. Builes-Montaño, Alejandro Vélez-Hoyos

Producción científica: Contribución a una revista › Artículo en revista científica indexada › revisión exhaustiva

Resumen

The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.

Título traducido de la contribución	Subacute thyroiditis and thyrotoxicosis after SARS-CoV-2 vaccine: report of 2 cases
Idioma original	Español
Páginas (desde-hasta)	383-389
Número de páginas	7
Publicación	Medicina y Laboratorio
Volumen	26
N.º	4
DOI	https://doi.org/10.36384/01232576.609
Estado	Publicada - 2022
Publicado de forma externa	Sí

Nota bibliográfica

Publisher Copyright:
© 2022, Universidad de Antioquia. All rights reserved.

Palabras clave

COVID-19
adenovirus
goiter
messenger RNA
thyroiditis
vaccine

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.36384/01232576.609

Citar esto

@article{ac308b7a712248f38f8d54448f8ff2ef,

title = "Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos",

abstract = "The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.",

keywords = "COVID-19, adenovirus, goiter, messenger RNA, thyroiditis, vaccine",

author = "Rueda-Galvis, {Myriam Vanessa} and Ram{\'i}rez-S{\'a}nchez, {Isabel Cristina} and Builes-Monta{\~n}o, {Carlos E.} and Alejandro V{\'e}lez-Hoyos",

year = "2022",

doi = "10.36384/01232576.609",

language = "Espa{\~n}ol",

volume = "26",

pages = "383--389",

journal = "Medicina y Laboratorio",

issn = "0123-2576",

publisher = "Universidad de Antioquia",

number = "4",

}

Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos. / Rueda-Galvis, Myriam Vanessa; Ramírez-Sánchez, Isabel Cristina; Builes-Montaño, Carlos E. et al.
En: Medicina y Laboratorio, Vol. 26, N.º 4, 2022, p. 383-389.

Producción científica: Contribución a una revista › Artículo en revista científica indexada › revisión exhaustiva

TY - JOUR

T1 - Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2

T2 - reporte de 2 casos

AU - Rueda-Galvis, Myriam Vanessa

AU - Ramírez-Sánchez, Isabel Cristina

AU - Builes-Montaño, Carlos E.

AU - Vélez-Hoyos, Alejandro

PY - 2022

Y1 - 2022

N2 - The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.

AB - The SARS-CoV-2 coronavirus disease which emerged in 2019 (COVID-19), has forced the rapid development of vaccines to prevent the spread of infection and attempt to control the pandemic. Among the vaccines developed, one of the first to be approved with a new technology in the field of vaccination, was the mRNA (messenger ribonucleic acid) vaccine, with rates of effectiveness close to 95% for the prevention of severe COVID-19 disease. Common adverse events are mild local reactions, but there have been some reports of patients developing sub-acute thyroiditis and thyroid dysfunction after receiving the SARS-CoV-2 vaccine. This article presents two case reports of subacute thyroiditis shortly after receiving the COVID-19 vaccine.

KW - COVID-19

KW - adenovirus

KW - goiter

KW - messenger RNA

KW - thyroiditis

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85159310033&partnerID=8YFLogxK

U2 - 10.36384/01232576.609

DO - 10.36384/01232576.609

M3 - Artículo en revista científica indexada

AN - SCOPUS:85159310033

SN - 0123-2576

VL - 26

SP - 383

EP - 389

JO - Medicina y Laboratorio

JF - Medicina y Laboratorio

IS - 4

ER -

Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos

Resumen

Nota bibliográfica

Palabras clave

ODS de las Naciones Unidas

Acceder al documento

Huella

Citar esto